EyePoint Pharmaceuticals Q3 EPS $(0.33) Beats $(0.51) Estimate, Sales $15.20M Beat $7.52M Estimate
Portfolio Pulse from Benzinga Newsdesk
EyePoint Pharmaceuticals reported Q3 losses of $(0.33) per share, beating the analyst consensus estimate of $(0.51) by 35.29%. This is a 32.65% increase over losses from the same period last year. The company also reported quarterly sales of $15.20 million, beating the analyst consensus estimate of $7.52 million by 102.15%. This is a 51.84% increase over sales from the same period last year.
November 01, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EyePoint Pharmaceuticals reported better than expected Q3 results, with losses and sales both beating estimates.
EyePoint Pharmaceuticals reported Q3 results that beat analyst estimates. This positive financial performance could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100